`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`
`ACUITAS THERAPEUTICS INC.,
`
`Plaintiff,
`
`v.
`
`GENEVANT SCIENCES GMBH AND
`ARBUTUS BIOPHARMA CORP.,
`
`Case No. 1:22-CV-02229-ER
`
`
`
`
`
`
`
`Defendants.
`
`
`RULE 7.1 CORPORATE DISCLOSURE STATEMENT
`
`Defendant Arbutus Biopharma Corp. (“Arbutus”) submits the following statement of its
`
`corporate interests pursuant to Rule 7.1 of the Federal Rules of Civil Procedure.
`
`Arbutus hereby states that it has no parent corporation. Roivant Sciences Ltd., a
`
`publicly-held company, owns 10% or more of the stock of Arbutus Biopharma Corp.
`
`
`Dated: April 15, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`/s/ Kira A. Davis
`DURIE TANGRI LLP
`Kira A. Davis
`953 East 3rd Street
`Los Angeles, CA 90013
`Telephone: (213) 992-4499
`Facsimile: (415) 236-6300
`Email: kdavis@durietangri.com
`
`Attorney for Defendant
`ARBUTUS BIOPHARMA CORP.
`
`1
`
`
`
`Case 1:22-cv-02229-MKV Document 22 Filed 04/15/22 Page 2 of 2
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on April 15, 2022 the within document was filed with the Clerk of
`
`the Court using CM/ECF which will send notification of such filing to the attorneys of record in
`
`this case.
`
`
`
`/s/ Kira A. Davis
`KIRA A. DAVIS
`
`2
`
`